Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Last-Resort drug made available for lymphoma patients

NCT ID NCT05619367

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack cancer cells. The goal is to offer a potential treatment when standard therapies are no longer working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
odronextamab (a drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could provide a treatment option for patients with certain lymphomas who have run out of standard therapies.
What could go wrong
This is a compassionate use program, not a formal trial, so results are not systematically collected. It may not work for everyone and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell non-Hodgkin lymphoma (NHL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell non-Hodgkin lymphoma (NHL) Diffuse large B cell lymphoma (DLBCL) High-grade B-cell lymphoma (HGBCL) Relapsed or refractory (R/R) follicular lymphoma (FL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.